At Roche, we are privileged to work alongside people living with Alzheimer’s disease, their care
partners, and the wider community. Tackling the challenges of Alzheimer’s requires a
combination of scientific innovation, empathy, and meaningful engagement with those it affects.
Our approach is guided by the insights and experiences shared by the Alzheimer’s community.
Whether we are developing new diagnostics, researching treatments, or designing supportive
resources, these collaborations ensure that we stay focused on what truly matters to people
living with this disease and those supporting them.
We aspire to be more than a research organization, we want to be a partner that people can
trust. While progress takes time, we are dedicated to working hand-in-hand to make a tangible
difference.
While we focus on Alzheimer’s disease specifically, we recognize that this disease is part of the
broader spectrum of dementia conditions, which impacts millions of people worldwide.
Learning from the Alzheimer’s Community
Listening and taking action
Engaging directly with patient and carer organizations like ADI as well as people affected by
Alzheimer’s and their loved ones has reshaped how we work and made our efforts more
relevant and impactful. These partnerships have helped us improve in several key areas:
- Making clinical trials more accessible: Feedback from individuals, care partners, and
patient organizations has fundamentally influenced how we design our studies. Their
insights go beyond logistical considerations, they help us shape trials that prioritize
inclusivity, relevance, and participant well-being. From simplifying study procedures to
creating materials with the community, we continuously strive to ensure clinical trials
align with the real-world needs of those involved. - Choosing words carefully: Partnering with advocates such as ADI, has reinforced the
importance of using language that is considerate, accessible, and inclusive. Thoughtful
communication not only builds trust but also helps address stigma. - Recognizing care partner challenges: Our collaborations with care partners have
highlighted the mental, emotional, and logistical burdens they face daily. These insights
remind us to develop solutions that go beyond scientific innovation and address the
broader needs of the community.
Commitment to Representation and Equity in Research
Diverse representation in research is essential for creating solutions that work for everyone. By
working with trusted organizations in underrepresented communities, we aim to ensure our
clinical studies reflect the people most impacted by Alzheimer’s. Generating robust,
representative data is key to developing treatments that are equitable and effective.
Moving forward together
We know there are no quick fixes when it comes to Alzheimer’s disease. This is a complex
disease that demands persistence, creativity, and sustained collaboration. What drives us is the
determination of the Alzheimer’s community, whose input continues to shape our work and
improve what we can offer.
We are committed to listening, learning, and broadening our understanding. By working closely
with people living with Alzheimer’s, care partners, and advocacy groups, we will continue
striving for progress, step by step, towards practical and meaningful solution
Links to Further Information:
Portraits of Care – Research Study with Alzheimer’s Disease International & University
of Westminster
This multi-country study explores the experiences of care partners of people with
Alzheimer’s in Brazil, South Africa, the UK, and the US using both qualitative and
quantitative methods.
Recommendations to Ensure Meaningful Collaborative Working Between the
Pharmaceutical Industry and Patient Organisations
Designing Clinical Trials with the Alzheimer’s Community
How rethinking Alzheimer’s clinical trial design and delivery can improve the experience
for participants and their study partners.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded
medicines, Roche has grown into the world’s largest biotechnology company and the global
leader in in-vitro diagnostics. The company pursues scientific excellence to discover and
develop medicines and diagnostics for improving and saving the lives of people around the
world. We are a pioneer in personalised healthcare and want to further transform how
healthcare is delivered to have an even greater impact. To provide the best care for each person
we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with
data insights from the clinical practice.
For more information, please visit: www.roche.com
About Roche in Alzheimer’s Disease
With more than two decades of scientific research in Alzheimer’s disease, Roche is working
towards a day when we can detect and treat the disease early, in order to slow down, stop or
even prevent its progression to preserve what makes people who they are. Today, the
company’s Alzheimer’s disease portfolio spans investigational medicines for different targets,
types and stages of the disease. On the diagnostics side, it also includes approved and
investigational tools, including digital and blood-based tests and CSF assays, aiming to more
effectively detect, diagnose and monitor the disease. Yet the global challenges of Alzheimer’s
disease go well beyond the capabilities of science, and making a meaningful impact requires
collaboration both within the Alzheimer’s community and outside of healthcare. Roche will
continue to work together with numerous partners with the hope to transform millions of lives